Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase 1 Study of Nilotinib in Combination With Dabrafenib and Trametinib or Encorafenib/Binimetinib in BRAF V600 Mutant Metastatic Melanoma After Progression on BRAF/MEK Inhibition
This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresecta…
Metastatic MelanomaBRAF Gene Mutation
Rina PlattnerNCT04903119
Phase 1
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales ServierNCT05786924